DURHAM, N.C., Nov. 26, 2024 /PRNewswire/ -- Target RWE, a leader in real-world evidence (RWE) solutions in liver disease and gastroenterology, shared the latest research derived from its metabolic dysfunction-associated steatohepatitis (MASH) and eosinophilic gastrointestinal diseases...
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries
Seaking AlphaSeeking Alpha / Seaking Alpha 14 hours ago 1 Views
Comments